
The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients. OLUMIANT is a once-daily, oral JAK inhibitor developed by Incyte (NASDAQ:INCY) and licensed to Eli Lilly and Company (NYSE:LLY).
The regulatory approval is supported by results from Phase 3 studies of ACTT@ and COV-BARRIER. No new safety signals potentially related to the use of OLUMIANT were identified in the studies.